The Efficacy and Safety of Venetoclax Therapy in Elderly Patients with Relapsed, Refractory Chronic Lymphocytic Leukaemia

Overview

Journal Br J Haematol

Specialty Hematology

Date 2019 Nov 5

PMID 31682002

Citations 8

Authors

Toby A Eyre

Lindsey E Roeker

Christopher P Fox

Satyen H Gohill

Renata Walewska

Harriet S Walter

Francesco Forconi

Angus Broom

Arvind Arumainathan

Danielle M Brander

John N Allan

Stephen J Schuster

Brian T Hill

Frederick Lansigan

Bruce D Cheson

Nicole Lamanna

Catherine C Coombs

Paul M Barr

Alan P Skarbnik

Mazyar Shadman

Chaitra S Ujjani

Laurie Pearson

John M Pagel

Ryan Jacobs

Anthony R Mato

Affiliations

Soon will be listed here.

Abstract

Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and <75 years treated in the relapsed, refractory non-trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib-exposed and therefore may otherwise have few clear therapeutic options.

Citing Articles

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.

Chatzikonstantinou T, Scarfo L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J Hemasphere. 2024; 8(9):e70004.

PMID: 39290716 PMC: 11405932. DOI: 10.1002/hem3.70004.

LC-MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study.

Alnasser A, Hefnawy M, Al-Hossaini A, Bin Jardan Y, El-Azab A, Abdel-Aziz A Saudi Pharm J. 2023; 31(9):101693.

PMID: 37559870 PMC: 10407895. DOI: 10.1016/j.jsps.2023.06.026.

Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method.

Yang X, Mei C, He X, He L, Lu X, Tong H Molecules. 2022; 27(5).

PMID: 35268708 PMC: 8911561. DOI: 10.3390/molecules27051607.

Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review.

Fresa A, Autore F, Galli E, Tomasso A, Stirparo L, Innocenti I J Clin Med. 2021; 10(21).

PMID: 34768624 PMC: 8584288. DOI: 10.3390/jcm10215104.

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting.

Tong J, Zhao N, Hu X, Yao W, Cheng Y, Zhou L Cancer Manag Res. 2021; 13:5613-5621.

PMID: 34285581 PMC: 8285225. DOI: 10.2147/CMAR.S316561.

References

Woyach J, Ruppert A, Heerema N, Zhao W, Booth A, Ding W . Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26):2517-2528. PMC: 6325637. DOI: 10.1056/NEJMoa1812836. View

Davids M, Hallek M, Wierda W, Roberts A, Stilgenbauer S, Jones J . Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018; 24(18):4371-4379. DOI: 10.1158/1078-0432.CCR-17-3761. View

Eyre T, Kirkwood A, Gohill S, Follows G, Walewska R, Walter H . Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019; 185(4):656-669. DOI: 10.1111/bjh.15802. View

Schemper M, Smith T . A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-6. DOI: 10.1016/0197-2456(96)00075-x. View

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L . Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2018; 20(1):43-56. DOI: 10.1016/S1470-2045(18)30788-5. View

Mato A, Thompson M, Allan J, Brander D, Pagel J, Ujjani C . Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018; 103(9):1511-1517. PMC: 6119152. DOI: 10.3324/haematol.2018.193615. View

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour J, Munir T . Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016; 17(6):768-778. DOI: 10.1016/S1470-2045(16)30019-5. View

Mato A, Nabhan C, Thompson M, Lamanna N, Brander D, Hill B . Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018; 103(5):874-879. PMC: 5927982. DOI: 10.3324/haematol.2017.182907. View

Jones J, Mato A, Wierda W, Davids M, Choi M, Cheson B . Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2017; 19(1):65-75. PMC: 6027999. DOI: 10.1016/S1470-2045(17)30909-9. View

10.

Fischer K, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M . Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019; 380(23):2225-2236. DOI: 10.1056/NEJMoa1815281. View

11.

Maddocks K, Ruppert A, Lozanski G, Heerema N, Zhao W, Abruzzo L . Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015; 1(1):80-7. PMC: 4520535. DOI: 10.1001/jamaoncol.2014.218. View

12.

Roeker L, Fox C, Eyre T, Brander D, Allan J, Schuster S . Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019; 25(14):4264-4270. PMC: 8020996. DOI: 10.1158/1078-0432.CCR-19-0361. View

13.

Coutre S, Choi M, Furman R, Eradat H, Heffner L, Jones J . Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018; 131(15):1704-1711. PMC: 5922273. DOI: 10.1182/blood-2017-06-788133. View

14.

Freise K, Shebley M, Salem A . Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. J Clin Pharmacol. 2017; 57(6):796-804. DOI: 10.1002/jcph.858. View

15.

Roberts A, Ma S, Kipps T, Coutre S, Davids M, Eichhorst B . Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019; 134(2):111-122. PMC: 6624969. DOI: 10.1182/blood.2018882555. View